Episode
A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith
- Podcast
- Business Of Biotech
- Published
- Jan 12, 2026
- Duration seconds
- 3524
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/a-royalty-model-for-value-creation-with-zymeworks-kenneth-galbraith/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/a-royalty-model-for-value-creation-with-zymeworks-kenneth-galbraith.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene), J&J, Merck, Daiichi Sankyo, and GSK. Ken talks about Zymeworks' shift to a royalty model for development funding and value creation, lessons learn...